InHealth Group and CTI have agreed to jointly develop seven new PET and PET/CT centers in the U.K. and to collaborate in the management of existing InHealth imaging centers to provide PET and PET/CT services. Onsite manufacturing facilities using CTI
InHealth Group and CTI have agreed to jointly develop seven new PET and PET/CT centers in the U.K. and to collaborate in the management of existing InHealth imaging centers to provide PET and PET/CT services. Onsite manufacturing facilities using CTI technology will produce positron radioisotopes, including FDG. The new centers will be established in close collaboration with the U.K.'s major National Health Service trusts and leading academic institutions. Additionally, the two companies will support a U.K.-wide mobile scanning service. Both the mobile service and the first scanning center are already operational, and InHealth has already carried out more than 2000 PET scans. InHealth will utilize CTI's cyclotron and chemistry technology and expertise in the development of new PET tracer production, pharmacy, and distribution facilities.
Study Shows No Impact of Hormone Therapy on PET/CT with 18F-Piflufolastat in PCa Imaging
May 7th 2025For patients with recurrent or metastatic prostate cancer, new research findings showed no significant difference in the sensitivity of 18F-piflufolastat PET/CT between patients on concurrent hormone therapy and those without hormone therapy.